Hepatitis C deaths fall 16% in two years

Deaths from serious hepatitis C related liver disease fell from 380 to 319 between 2015 and 2017, thanks to new curative treatments.
Source: NHS Networks - Category: UK Health Source Type: news

Related Links:

ConclusionHCV treatment in a large community-based cohort demonstrated sustained improvements in AST, ALT, PLT, and FIB-4. Rebound increases in AST, ALT, and FIB-4 observed in Hispanics and those with BMI>30 kg/m2 may reflect persisting nonalcoholic fatty liver disease.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
This study was conducted to clarify the association of SNPS of TLR2 and TLR4 with clinical outcome of hepatitis C, response to treatment and development of HCC. Methods: The current study examined 3295 individuals from 725 families that were categorized into groups comprising chronic HCV (CH), spontaneous viral clearance (SC) and control subjects. Treated patients were classified into responders (RT) and non-responders (NRT). In addition, patients with liver cirrhotic (LC), and hepatocellular carcinoma (HCC) were also included. All subjects were genotyped for five single nucleotide polymorphisms (SNPs) of TLR2 and four SNP...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
Authors: Kawaguchi T, Ide T, Kondo R, Nomura Y, Arinaga-Hino T, Kuwahara R, Amano K, Sano T, Akiba J, Ohshima K, Yano H, Torimura T Abstract Although the incidence of hepatocellular carcinoma (HCC) occurring after hepatitis C virus (HCV) eradication has decreased, there are still reports of hepatocarcinogenesis. The present study investigated the histological changes of non-cancerous liver tissue obtained prior to interferon (IFN) therapy and after HCC development. A total of 669 HCV-infected Japanese patients who achieved sustained virological response (SVR) by IFN-based therapy were retrospectively enrolled. Of t...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
CONCLUSIONS: Clinical trials assessing zinc supplementation in liver diseases do not show benefits in terms of clinical improvement or disease halting. There are possible benefits of zinc supplementation on hepatic encephalopathy, however, this is based on limited evidence. This research question is still open for evaluation in larger, well-designed, clinical trials. PMID: 31611064 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Direct-acting antivirals (DAA) have become the new standard of care for patients with chronic hepatitis C virus (HCV) infection, demonstrating to be highly effective in achieving sustained virological response (SVR) rates regardless of HCV-genotype. Due to their safety profile and low side effects any patient in any stage of chronic liver disease (from mild fibrosis to decompensated cirrhosis) can be treated with DAA [1]. Therefore, it is important to know which patients will be prone to develop liver-related complications, such hepatocellular carcinoma (HCC) or liver decompensation, and will need a lifelong follow up and ...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Authors: De Pace V, Morelli MC, Ravaioli M, Maggi F, Galli S, Vero V, Re MC, Cescon M, Pistello M Abstract Safety, efficacy, and predictor factors of sustained-virological-response after 24 weeks of new directacting antivirals were evaluated in hepatitis C virus patients with different stages of hepatic disease. 260 patients, median age 60 years, of whom 48.1% cirrhotics, 17.7% liver transplant recipients, and 45.7% naïve were treated with Sofosbuvir+Ribavirine, Sofosbuvir+Simeprevir±Ribavirine, Sofosbuvir+Daclatasvir±Ribavirine, Sofosbuvir+Ledispavir±Ribavirine, Ombitasvir/Paritaprevir/Ri...
Source: New Microbiologica - Category: Microbiology Tags: New Microbiol Source Type: research
FDA has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic Hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Publication date: Available online 9 October 2019Source: The Lancet Respiratory MedicineAuthor(s): Marcelo Cypel, Jordan J Feld, Marcos Galasso, Rafaela V Pinto Ribeiro, Nikki Marks, Magdalena Kuczynski, Deepali Kumar, Ilona Bahinskaya, Vanderlei S Bagnato, Cristina Kurachi, Arthur S S.sky, Jonathan C Yeung, Laura Donahoe, Marc de Perrot, Kazuhiro Yasufuku, Andrew Pierre, Matthew Binnie, Cecilia Chaparro, Tereza Martinu, Manyin ChenSummaryBackgroundA substantial proportion of organ donors test positive for hepatitis C virus (HCV) infection. To date, only a few studies have evaluated the safety of using lungs from these don...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
AbstractBackground and AimsLiver cirrhosis is a substantial health burden in the USA, but population-based data regarding the trend and medical expenditure are limited and outdated. We investigated the trends of inpatient admissions, costs, and inpatient mortality from 2005 to 2015 among cirrhotic patients.MethodsA retrospective analysis was conducted using the National Inpatient Sample database. We adjusted the costs to 2015 US dollars using a 3% inflation rate. National estimates of admissions were determined using discharge weights.ResultsWe identified 1,627,348 admissions in cirrhotic patients between 2005 and 2015. Fr...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Hospital admissions because of alcohol-related liver disease (ArLD) are increasing. The amount of alcohol consumed and pattern of drinking are linked to increased risk of ArLD. However, other factors such as obesity, co-existent liver disease – particularly hepatitis C, gender, nutritional status and genetic factors also play a role. The spectrum of ArLD ranges from steatosis to alcoholic hepatitis to established cirrhosis, and the alcohol-related injury involves multiple mechanisms. Chronic, excessive alcohol consumption can cause cir rhosis in the absence of alcohol dependency syndrome or indicators of alcohol abuse.
Source: Medicine - Category: Internal Medicine Authors: Tags: Common European liver disorders Source Type: research
More News: Hepatitis | Hepatitis C | Liver | Liver Disease | UK Health | Urology & Nephrology